Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02960659 |
|
Recruitment Status :
Recruiting
First Posted : November 10, 2016
Last Update Posted : January 10, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Background:
The pill metformin treats diabetes. But it does not work for all youth, especially African-Americans. The injectable Liraglutide treats type 2 diabetes in adults. Researchers want to understand how these drugs work and if they decrease excess sugar made by the liver in youth with type 2 diabetes.
Objective:
To test if using liraglutide and metformin are better than just metformin for decreasing excess sugar produced by the liver in African-American youth with type 2 diabetes.
Eligibility:
African-Americans ages 12-21 with type 2 diabetes
Design:
Visit 1: Participants will be screened with medical history, physical exam, and blood and urine tests.
Participants will stop taking diabetes medicines for 1 week. They will learn how to check blood sugars at home twice a day.
Visit 2: Overnight at the clinic. Participants will have:
Vital signs taken.
Pregnancy test.
A thin plastic tube (IV catheter) be inserted in each forearm by needle.
Blood drawn several times after drinking a sweet drink.
X-ray of total body fat.
Urine and stool collected.
Breath tests while wearing a clear hood for up to 45 minutes.
For several hours, participants can have only water. At 4 a.m. they will get sugar and fat with nonradioactive isotopes in one IV. Blood will be collected. Every 30 minutes from 9 a.m. to 2 p.m., they will drink small amounts of a shake and have blood drawn.
Participants will be randomly assigned to take either both study drugs daily or just metformin daily.
Visits 3-4: Participants will bring their blood sugar records and have blood tests.
Visit 5, after 3 months: Repeat of visit 2....
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Type 2 Diabetes | Drug: Metformin and Liraglutide Drug: Metformin | Phase 1 |
Type 2 Diabetes in youth is an emerging public health concern that disproportionately affects minority children. Among minority youth, African-Americans have the highest complication rates, yet the reasons underlying this health disparity are not fully understood. Furthermore, current treatment options are limited and African-American youth have high treatment failure rates. Metformin therapy is the only oral diabetes drug approved for use in youth with type 2 diabetes. However, metformin works less than 50% of the time in African-American youth and there is marked variability among individuals. Improving outcomes in youth requires understanding the way that drugs such as metformin work in youth and why it does not work in some individuals. New evidence suggests that the ability of metformin to work effectively may be influenced by certain genes or differences in gut bacteria. However, little is known about how genes or gut bacteria may affect youth, especially African-Americans.
To treat this aggressive disease, it is also necessary to simultaneously evaluate new therapeutic options, such as combination therapy of metformin with liraglutide in youth at highest risk for complications. Liraglutide is approved to treat type 2 diabetes in patients 10 years and older as an adjunct to diet and exercise. Liraglutide may be a useful early treatment in youth with type 2 diabetes because it may decrease glucose produced by the liver (an early prominent feature of type 2 diabetes in youth). This study is designed to examine the mechanism of action in the liver of these 2 agents and explore how genetic and gut factors may influence this action.
The primary objective of this pilot study is to compare the ability of two anti-diabetic regimens (metformin and liraglutide versus metformin alone) to lower gluconeogenesis (glucose produced by the liver) in African-American youth with type 2 diabetes. The secondary objectives are to evaluate the effect of these regimens on the following: (1) hepatic glucose production, and insulin sensitivity and (2) insulin and gut hormones concentrations (e.g. incretins). In addition, we will examine the relationship of known differences in genes associated with metformin transport and action with changes in gluconeogenesis and begin to explore the role of gut bacteria to metformin s glucose-lowering effect.
The study design is a parallel-randomized intervention trial of African-American youth with type 2 diabetes who are not on insulin therapy and who are within 5 years of diagnosis. Patients aged 12-25 years with type 2 diabetes will be enrolled. Participants will be randomized into two intervention arms (16 in each group): metformin and liraglutide versus metformin alone. The study will consist of 5 visits. At Visit 1, a medical history, physical examination and screening labs will be done. Then the eligible participants will undergo a one-week drug-free run-in. At Visit 2 there will be an overnight inpatient stay to perform metabolic testing prior to starting the study drug(s). Participants will start the study drug(s) immediately after Visit 2 and remain on the study drug(s) for 12 weeks. Follow-up monitoring will be performed at 4 week intervals (Visit 3 and 4). The final visit (Visit 5) will occur after 12 weeks.
To further explore metformin s action on the gut, a sub-study will compare youth treated with metformin to average-age-matched control youth with abnormal glucose tolerance (prediabetes or type 2 diabetes) who are not on or receiving metformin therapy. Youth on metformin will be seen for 5 outpatient visits and youth who are not on metformin will be seen for 2 outpatient visits.
The ultimate goal of this project is to begin to address diabetes disparities in African-American youth by understanding the mechanism of action of these diabetes agents to inform precision medicine initiatives. This project brings together the skills and expertise of investigators within the National Institute of Diabetes and Digestive Disorders and Kidney Diseases (NIDDK), the National Human Genome Research Institute (NHGRI) and the Children s National Medical Center (CNMC).
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 92 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Basic Science |
| Official Title: | Therapeutic Targets in African-American Youth With Type 2 Diabetes |
| Actual Study Start Date : | May 9, 2017 |
| Estimated Primary Completion Date : | December 31, 2022 |
| Estimated Study Completion Date : | December 31, 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: 1
RCT: Metformin and liraglutide vs. metformin alone
|
Drug: Metformin and Liraglutide
Randomized controlled trial of metformin + liraglutide vs. metformin alone over 3 months in youth with type 2 diabetes. Drug: Metformin Paired study of metformin over 3 months in youth with type 2 diabetes compared to controls (youth with prediabetes or type 2 diabetes not treated with metformin). |
|
Experimental: 2
Substudy: Metformin treated vs. control (no treatment)
|
Drug: Metformin
Paired study of metformin over 3 months in youth with type 2 diabetes compared to controls (youth with prediabetes or type 2 diabetes not treated with metformin). |
- Change in stool short-chain fatty acids (Propionate, butyrate, acetate) [ Time Frame: 12 weeks ]Substudy (paired nonrandomized protocol): To compare stool short-chain fatty acid (propionate, butyrate, acetate) concentrations after 3 months of metformin therapy compared to controls.
- Change in gluconeogenesis from baseline to 12 weeks [ Time Frame: 12 weeks ]The change in gluconeogenesis from baseline (prior to study drugs) to 12 weeks
- Change in glucose production from baseline to 12 weeks. [ Time Frame: 12 weeks ]
- Change in gut microbiota diversity (Shannon index) [ Time Frame: 12 weeks ]Substudy: To compare the gut microbiota diversity as measured by Shannon index, after 3 months of metformin therapy compared to controls.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 12 Years to 25 Years (Child, Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
-
INCLUSION CRITERIA:
- Youth must self-identify as African-American and identify both parents as African-American
- Age 12-25 years
- Pubertal or post-pubertal: Girls Tanner stage IV-V breast; Boys Testicular volume 11-25cc
- Diagnosis of type 2 diabetes of less than or equal to 5 years duration, as per American Diabetes Association Criteria
- Hemoglobin A1C <9% at study initiation
- Negative to mild ketonuria without acidosis (negative or 1+ ketones on urinalysis)
- Negative test for diabetes-related autoantibodies (glutamic acid decarboxylase 65 and tyrosine phosphataserelated islet antigen 2 (IA-2))
- Willing and able to take daily medications and check blood glucose levels at least twice per day or wear a continuous glucose monitoring device (CGM).
EXCLUSION CRITERIA:
- Pregnancy or breastfeeding
- Allergy to study medications
- Allergy to milk protein
- Chronic insulin therapy
- Treatment with other medications which are known to affect the parameters under study (for example sodiumglucose transporter 2 (SGLT-2) inhibitors, dipeptidyl peptidase-4 (DPP-IV) inhibitors, non-selective beta blockers).
- Metabolic derangement such as metabolic acidosis, severe hyperglycemia (fasting blood glucose greater than or equal to 200mg/dL), and/or liver enzymes > three times the upper limit of normal.
- Personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2
- Any other condition that, in the opinion of the investigators, will increase risk to the subject, or impede the accurate collection of study-related data.
- Body weight greater than or equal to 450 lbs
- Body weight less than or equal to 58kg
- Serum triglyceride concentrations greater than or equal to 500mg/dl
- Hemoglobin concentration <11g/dL
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02960659
| Contact: Stephanie T Chung, M.D. | (240) 479-8137 | stephanie.chung@nih.gov |
| United States, Maryland | |
| National Institutes of Health Clinical Center | Recruiting |
| Bethesda, Maryland, United States, 20892 | |
| Principal Investigator: | Stephanie T Chung, M.D. | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Additional Information:
| Responsible Party: | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| ClinicalTrials.gov Identifier: | NCT02960659 |
| Other Study ID Numbers: |
170013 17-DK-0013 |
| First Posted: | November 10, 2016 Key Record Dates |
| Last Update Posted: | January 10, 2020 |
| Last Verified: | December 27, 2019 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Diabetes Metformin Glucose |
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Metformin |
Liraglutide Hypoglycemic Agents Physiological Effects of Drugs Incretins Hormones Hormones, Hormone Substitutes, and Hormone Antagonists |